文献速递心脑血管急症重症综合管理与镇静镇痛

CN-105治疗急性幕上脑出血的2b期随机双盲安慰剂对照试验(S-CATCH)

CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage Trial in Singapore (S-CATCH): A Phase 2b, Randomized, Double-blind, Placebo-Controlled Trial.
PubMed 文献 · Neurocrit Care · 2026-06-23
一句话结论2b期试验显示CN-105在急性幕上脑出血中安全可行,虽90天mRS无显著改善,但院内神经功能恶化有减少趋势(0 vs 10%)。

S-CATCH是一项在新加坡进行的2b期随机双盲安慰剂对照试验,共纳入60例急性幕上脑出血患者(30例CN-105,30例安慰剂),在症状发作12小时内给药。CN-105是一种基于载脂蛋白E受体结合区设计的神经保护抗炎五肽。主要安全性终点显示两组严重不良事件发生率无显著差异(安慰剂30% vs CN-105 26.7%),CN-105组院内神经功能恶化更少(0 vs 10%)。90天mRS≤3的比例CN-105组为77.8%,安慰剂组为66.7%(p=0.35),未达统计学显著。作者认为观察到的趋势值得进一步研究,未来3期试验应聚焦于优化患者选择,如中等大小皮质下脑出血亚组。

要点

  • CN-105在急性幕上脑出血症状发作12小时内给药安全可行,严重不良事件发生率与安慰剂无显著差异(安慰剂30% vs CN-105 26.7%)。
  • CN-105组院内神经功能恶化发生率为0,安慰剂组为10%。
  • 90天mRS≤3(良好功能结局)比例CN-105组77.8%,安慰剂组66.7%,差异无统计学意义(p=0.35)。
  • 作者认为观察到的趋势值得进一步研究,未来3期试验应聚焦于优化患者选择,如中等大小皮质下脑出血亚组。

适用人群与场景

  • 急性原发性幕上脑出血患者,在症状发作12小时内接受治疗。
  • 共60例患者随机分组(30例CN-105,30例安慰剂)。

处置流程与药物剂量

  • CN-105为神经保护抗炎五肽,设计自载脂蛋白E受体结合区,在症状发作12小时内给药;原文未报告具体剂量、给药途径和频次。

研究设计与关键结果

  • 研究类型:2b期随机双盲安慰剂对照试验(S-CATCH,NCT03711903),共60例患者(30例CN-105,30例安慰剂),在症状发作12小时内治疗。
  • 主要安全性结果:严重不良事件发生率安慰剂组30% vs CN-105组26.7%,无显著差异。
  • 关键次要结果:院内神经功能恶化CN-105组0 vs 安慰剂组10%。
  • 90天mRS≤3比例:CN-105组77.8% vs 安慰剂组66.7%,p=0.35,未达统计学显著。

证据类型、等级与局限

  • 证据类型:2b期随机双盲安慰剂对照试验。
  • 局限:原文未报告局限性。
  • 作者结论:观察到的趋势值得进一步研究,未来3期试验应聚焦于优化患者选择,如中等大小皮质下脑出血亚组。

对床旁实践的改变

  • 在急性幕上脑出血症状发作12小时内,CN-105显示出安全性和可行性,严重不良事件与安慰剂无显著差异。
  • CN-105未显著改善90天mRS,但院内神经功能恶化有减少趋势(0 vs 10%),作者认为值得进一步研究。
  • 作者建议未来3期试验聚焦于优化患者选择,如中等大小皮质下脑出血亚组。

指南或共识出处

  • S-CATCH试验(NCT03711903),注册于2018年10月16日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Subsequent to an intracerebral hemorrhage (ICH), a cascade of neuroinflammatory response drives the process of secondary brain injury. At present, no anti-inflammatory nor neuroprotective pharmacological interventions have been demonstrated to improve functional outcome after ICH. This Phase 2b study was designed to establish the safety and feasibility of CN-105, a neuroprotective and anti-inflammatory pentapeptide designed from the receptor binding region of apolipoprotein E, in patients with acute primary supratentorial ICH.

METHODS: The Singapore CN-105 in Participants with Acute Supratentorial ICH Trial (S-CATCH, NCT03711903) was a randomized, double-blind, placebo-controlled trial involving 60 patients (30 CN-105, 30 placebo) treated within 12 h of symptom onset. Safety was assessed through adverse events (AEs) and serious AEs (SAEs), while efficacy was evaluated using functional outcome measures, including the modified Rankin Scale (mRS) at 90 days.

RESULTS: CN-105 was safe and well tolerated in patients with acute ICH, with no significant differences in incidence of SAEs between groups (30% SAEs in placebo vs. 26.7% in CN-105). Notably, fewer patients treated with CN-105 group experienced in-hospital neurological deterioration (0 vs. 10% in placebo). While treatment was not associated with a statistically significant improvement in 90-day mRS, higher proportion of patients treated with CN-105 achieved favorable mRS scores (≤ 3) compared with those in the placebo group (77.8 vs. 66.7%; p = 0.35).

CONCLUSIONS: This Phase 2b trial confirmed the safety and feasibility of CN-105 administration in the acute setting of ICH. Although no statistically significant improvements in neurological outcomes were found, the observed trends warrant further investigation. Future Phase 3 trials should focus on refining patient selection and assessing the therapeutic efficacy of CN-105 in more targeted subgroups such as those with medium-sized subcortical ICH. Trial registration NCT03711903, https://clinicaltrials.gov/ https://clinicaltrials.gov/study/NCT03711903?term=NCT03711903&rank=1 . Registered 16 October 2018.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Cheong TM, James ML, Nehar S, et al. CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage Trial in Singapore (S-CATCH): A Phase 2b, Randomized, Double-blind, Placebo-Controlled Trial. Neurocrit Care. 2026. PMID: 42332280. doi:10.1007/s12028-026-02563-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。